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Tamoxifen is an eﬀective drug, both for preventing
and treating breast cancer, but its role in prevention is
limited by its side-eﬀect proﬁle, particularly related to
endometrial problems and thrombotic events. The ar-
omatase inhibitors oﬀer the promise of greater eﬃcacy
with fewer side-eﬀects. Loss of bone mineral density
leading to an increased fracture rate appears to be the
major side-eﬀect associated with aromatase inhibitors. It
will be important to learn how to manage this outcome
with DXA (dual energy X-ray absorptiometry) scans
and bisphosphonates, where appropriate. New studies in
this direction are ongoing.
1. Background
Tamoxifen is probably the most successful cancer
treatment currently available and has a low side-eﬀect
proﬁle. Data from the overview of all adjuvant trials [1]
indicated that for every 1000 hormone receptor-positive
women, 5 years of tamoxifen can be expected to lead to 78
fewer breast cancer deaths andonly one extra endometrial
cancer death, and one extra death from a pulmonary
embolism. However, prevention trials [2,3] have clearly
indicated that there are a range of less severe side-eﬀects
associated with tamoxifen and that the risk-beneﬁt is not
so clearly positive when used in the preventive setting.
Recent studies in the adjuvant setting have suggested that
the aromatase inhibitors may be more eﬀective than ta-
moxifen in preventing recurrence and new contralateral
tumours and have fewer side-eﬀects than tamoxifen.
2. Results
The best comparative data on aromatase inhibitors
vs tamoxifen come from the arimidex, tamoxifen,
alone or in combination (ATAC) trial [4]. This trial
randomised 9366 women into one of three arms:
anastrozole alone, tamoxifen alone, or the combina-
tion for 5 years. The results on eﬃcacy and side-eﬀects
have recently been published after a 47-month median
follow-up [5]. For receptor-positive women, anastro-
zole had a 22% lower hazard ratio than tamoxifen
(P=0.007). The frequency of predeﬁned side-eﬀects
that diﬀered signiﬁcantly between these two treatments
is shown in Table 1. Overall, anastrozole was better
tolerated than tamoxifen (P<0.001). Many of the side
eﬀects known to be associated with tamoxifen were
reduced to baseline levels (vaginal bleeding, en-
dometrial cancer, thromboembolic events). The num-
ber of endometrial cancers is particularly low, and
may reﬂect a protective eﬀect against this cancer as
well. It is too early to be conﬁdent, but the next
analysis (due in December 2004) in which almost all
women will have completed their 5 years of treatment
will provide substantially more information on this
outcome. Strokes and TIAs are also substantially re-
duced on anastrozole compared with tamoxifen
(P<0.001). It is not clear yet if this represents a re-
duction in strokes due to oestrogen depletion from
Table 1
Adverse events in ATAC Summary relative rates for Anastrozole
compared with tamoxifen
Reduced by anastrozole
Hot ﬂushes (34% vs 40%) down 14%
Vaginal bleeding (4.5% vs 8.1%) down 44%
Endometrial cancer (3% vs 15%) down 80%
Strokes/TIAs (1% vs 2%) down 50%
Thromboembolic events (2.1% vs 3.5%) down 40%
Stopping treatment (5% vs 7%) down 32%
Increased by qnastrozole
Musculo-skeletal (28% vs 21%) up 30%
All fractures (6% vs 4%) up 50%
ATAC, arimidex, tamoxifen, alone or in combination.
TIA: transient ischaemic attack.
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anastrozole or an increase due to tamoxifen, where the
data are currently mixed [2,6]. The placebo-controlled
prevention trial of anastrozole (IBIS-II) (International
Breast cancer Intervention Study) will be needed to
clarify this.
Against these favourable outcomes, one must weigh
the unfavourable eﬀects of oestrogen depletion on
musculo-skeletal events and fractures. The former
problem appears to be generally mild and has not led
to stopping treatment in the ATAC trial. However,
learning how best to manage bone loss and
the attendant increase in fracture rates is probably
the major new challenge for using aromatase
inhibitors.
This is being addressed in the IBIS-II prevention
trial in which 1000 women split into 3 strata will be
evaluated by sequential DXA scans and treatment
with the bisphosphonate risedronate (oral, weekly 35
mg) (Fig. 1). Adequate control of this side-eﬀect
would make an aromatase inhibitor a very useful
agent, both for the treatment and prevention of breast
cancer. The latter goal is the subject of the ongoing
IBIS-II trial involving the use of anastrozole or pla-
cebo in 6000 post-menopausal women at increased
risk of breast cancer.
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•  anastrozole 1mg or anastrozole placebo  
• All women are monitored with DXA scans at baseline, 1, 3, 5 & 7years 
•  Blood samples at baseline, 6 months & 12 months,  for measurement 
      of bone biomarkers 
• All women recommended to take calcium & vitamin D supplements 
•  Women will be divided into the three strata below; 
T score> - 1.5  
*No bisphosphonates
 
  initially  
   n=300 
-2.5 < T score < -1.5
 *Randomised to take 
  bisphosphonates or
   placebo 
 n=400 
T score  < -2.5 or  
 previous spinal 
  fragility fracture 




Fig. 1. IBIS II–Bone sub-study.
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